Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

References

• Bangsberg DR, Ragland K, Monk A, et al. A single-tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–2840.10.1097/QAD.0b013e328340a209
   PubMed Web of Science ®Google Scholar
• Sutton SS, Hardin JW, Bramley TJ, et al. Single-versus multiple-tablet HIV regimens: adherence and hospitalization risk. Am J Manage Care. 2016;22(4):242–248.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open. 2013;3:1–12.
   Web of Science ®Google Scholar
• Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the united states. PLoS ONE. 2012;7(2):1–10.
   Web of Science ®Google Scholar
• Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy. 2017;37(2):204–213.10.1002/phar.2017.37.issue-2
   PubMed Web of Science ®Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switch to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus continuation of nonnucleoside reverse transcriptase inhibitor plus emtricitabine/tenofovir DF in virologically suppressed HIV adults (STRATEGY-NNRTI): week 48 results of a randomized open-label phase 3b study. Lancet Infect Dis. 2014;14:590–599.
   PubMed Web of Science ®Google Scholar
• Arribas J, Pialoux G, Gathe J, et al. Simplification to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus continuation of ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF in virologically suppressed HIV adults (STRATEGY-PI): week 48 results of a randomized, open label phase 3b study. Lancet Infect Dis. 2014;14:581–589.
   PubMed Web of Science ®Google Scholar
• Lutz T, Benson P, Goffard JC, et al. Patient reported outcomes over 48 weeks in a randomized, open-label trial of patients with HIV switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) [poster PE7/1]. Paper presented at 15th European AIDS Conference (EACS); 21–24 October 2015, Barcelona, Spain.
   Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017. doi:10.3851/IMP3166.
   Google Scholar
• STRIBILD®, Gilead Sciences Inc. STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use. US Prescribing Information. Revised ed. Foster City, CA. 2017.
   Google Scholar
• DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429–2438.10.1016/S0140-6736(12)60918-0
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483–486.10.1097/QAI.0b013e318286415c
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs. ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121–e124.10.1097/QAI.0000000000000089
   PubMed Web of Science ®Google Scholar
• Sax P, DeJesus E, Mills A. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–2448; Erratum: Lancet. 2012;380:730.
   Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96–100.10.1097/QAI.0b013e318289545c
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–e120.10.1097/QAI.0000000000000057
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the DHHS panel on antiretroviral guidelines for adults and adolescents – a working group of the office of AIDS Research Advisory Council (OARAC). Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Last Updated July 14 2016.
   Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191–210.10.1001/jama.2016.8900
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). Guidelines Version 8.0 English. October 2015.
   Google Scholar
• Cockcroft D, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.10.1159/000180580
   PubMed Web of Science ®Google Scholar
• Dixon JR. The international conference on harmonization good clinical practice guideline. Qual Assur Good Pract Regul Law. 1999;6(2):65–74.
   Google Scholar
• Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–S90.10.1016/S0895-4356(01)00449-8
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Inc. Data on File.
   Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32–40.
   PubMed Web of Science ®Google Scholar
• Stray K, Bam R, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother. 2013;57(10):4982–4989.10.1128/AAC.00712-13
   PubMed Web of Science ®Google Scholar
• Lepist E-I, Murray BP, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [Poster A1-1724]. Paper presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 September 17–20, Chicago, IL.
   Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407.10.1016/S0140-6736(09)62041-9
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24(11):1697–1707.10.1097/QAD.0b013e32833a608a
   PubMed Web of Science ®Google Scholar
• González de Requena D, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDs. 2003;17(9):443–445.10.1089/108729103322395465
   PubMed Web of Science ®Google Scholar